Tag Archives: Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is sprouting some green shoots. But Valeant stock remains a risky bet.

Valeant Stock: The Rally May Be Over, But The Struggle Is Not


Flickr

Despite posting strong results, the troubles for Canada based specialty pharma company Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is far from over. In the last two trading sessions, shares of Canada basedtroubled drug makerhave lost over 7% after the company came out with a plan to raise more than $750 million in debt in a private offeringof 5.5% notes due in 2025. Valeant will use a part of the proceeds to pay down term loans due in 2022.

The recent correction has brought back Valeant stock below the 100-day moving average line. 100-day SMA hasprovided strong resistance....More>>>